Skip to main content
. 2023 Nov 22;9(47):eadi0889. doi: 10.1126/sciadv.adi0889

Fig. 6. UBE2O promotes tumor growth by mainly degrading L3MBTL2 in osteosarcoma.

Fig. 6.

(A) UBE2O mRNA levels were normalized to GAPDH levels in the paired osteosarcoma and normal tissues as determined by RT-qPCR. n = 33. Data are means ± SD. P values are shown. (B) Cell viability of the indicated stable cells was measured by MTT assay at the indicated time points. (C) Colony formation assay was performed for the indicated stable cells. The colony numbers per field were counted. Data in (B and C) are means ± SD of n = 3 biologically independent experiments. P values are shown. (D) The indicated 143B stable cells were analyzed by Western blotting. Data are representative of n = 3 biologically independent experiments. (E to G) The indicated 143B stable cells were subcutaneously injected into mice. (E) Tumor growth was measured at the indicated time points. (F) Representative images of xenograft tumors. (G) Tumor weight was measured at the end point. n = 6 biologically independent mice. Data are means ± SD. P values are shown. (H) Representative immunohistochemical images of both L3MBTL2 and UBE2O from 109 osteosarcoma tissues. (I) The correlation between L3MBTL2 and UBE2O protein levels in 109 osteosarcoma tissues from (I). P = 0.002, chi-square tests. R: Spearman correlation coefficient. (J) Overall survival curves were analyzed on the basis of UBE2O protein levels in patients with osteosarcoma by Kaplan-Meier method. Thirty-five and 54 cases with low and high expression of UBE2O, designed as UBE2O low expression and UBE2O high expression, respectively, were plotted, and P values are shown.